Saturday 17 October 2026
Export INM’s income statement to Excel — free account
InMed Pharmaceuticals Inc.
INM Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.32
0.01
−0.75%
Follow INM
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 2 | 5 | — |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
— | — | — | — | — | 0.00 | 0.55 | 0.42 | 0.51 | — |
Altman Z-Score |
— | — | — | — | — | (12.94) | (10.26) | (13.65) | (10.27) | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (27.11) | (16.79) | (27.28) | (16.96) | — |
Beneish M-Score |
— | — | — | — | — | — | 0.04 | (2.30) | (2.54) | — |
P/Operating CF |
— | — | — | — | — | (1.63) | (3.45) | (1.87) | (1.50) | — |
P/B ratio |
— | — | — | — | — | 0.73 | 0.19 | 0.21 | 0.24 | — |
Price to Tangible BV |
— | — | — | — | — | 0.95 | 0.22 | 0.26 | 0.27 | — |
EV/Sales |
— | — | — | — | — | 0.00 | (1.61) | (0.87) | (1.17) | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.81 | 0.51 | 1.24 | — |
EV/Operating CF |
— | — | — | — | — | (0.05) | 0.91 | 0.58 | 0.90 | — |
EV/FCF |
— | — | — | — | — | (0.05) | 0.89 | 0.57 | 0.89 | — |
Quick Ratio |
18.31 | 28.29 | 11.60 | 3.52 | 3.35 | 1.90 | 4.61 | 3.53 | 6.12 | 1.14 |
Current Ratio |
18.79 | 28.51 | 11.87 | 3.77 | 3.78 | 2.89 | 5.66 | 4.41 | 6.99 | 1.37 |
Net Debt/EBITDA |
1.57 | 3.01 | 1.46 | 0.62 | 0.74 | 0.34 | 1.09 | 0.75 | 1.27 | 0.20 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 3.18% | 1.94% | 3.05% | 0.11% | 5.45% | 1.96% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.04 | 0.00 | 0.07 | 0.02 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.31 | 0.35 | 0.36 | 0.00 |
Operating CF/Net income |
0.69 | 0.55 | 0.72 | 0.83 | 0.96 | 0.84 | 0.92 | 0.91 | 0.99 | 0.67 |
Capex/Depreciation |
0.00 | 0.00 | (0.22) | (0.37) | (0.01) | (0.21) | (0.79) | (0.04) | 0.00 | 0.00 |
Interest Coverage |
— | (195.05) | (38.15) | (96.81) | (27.58) | (231.75) | (22.63) | — | (22.74) | (1,061.03) |
| (96.99%) | (49.97%) | (61.94%) | (88.85%) | (153.95%) | (226.07%) | (75.09%) | (72.09%) | (72.10%) | (179.09%) | |
| (528.57%) | (59.29%) | (58.54%) | (76.93%) | (116.05%) | (164.83%) | (59.10%) | (59.20%) | (59.57%) | (139.63%) | |
ROIC |
0.00% | 0.00% | (1,299.62%) | (2,056.57%) | (3,974.05%) | (332.39%) | (166.31%) | (157.09%) | (178.73%) | 0.00% |
Return on Tangible Assets |
(66.34%) | (34.14%) | (71.02%) | (177.37%) | (157.22%) | (258.96%) | (79.05%) | (96.33%) | (67.91%) | (1,378.37%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.48 | 22.98 | 28.01 | 34.35 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 668.50% | 90.24% | 69.98% | 57.08% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 630.35% | 141.39% | 126.11% | 109.55% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.05 | 0.08 | 0.14 | 0.11 | 0.16 | 0.14 | 0.15 | 0.10 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 64.06% | 6.73% | 2.99% | 2.41% | 0.00% |
Graham Net Nets |
— | — | — | — | — | 0.89 | 4.10 | 3.16 | 3.38 | — |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | — | (282.30%) | (350.57%) | (6,271.61%) | (257.46%) | — |
Free Cash Flow Yield |
— | — | — | — | — | (236.61%) | (328.15%) | (365.94%) | (256.64%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.77 | 33.79 | 12.07 | 5.06 | 0.00 |
Operating CF per Share |
(0.61) | (16.14) | (636.95) | (709.11) | (730.64) | (554.58) | (59.50) | (18.34) | (8.30) | (2.08) |
Capex per Share |
0.00 | 0.00 | (2.58) | (4.04) | (0.13) | (1.39) | (1.31) | (0.02) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.61) | (16.14) | (639.53) | (713.14) | (730.77) | (555.98) | (60.81) | (18.36) | (8.30) | (2.08) |
Cash per Share |
1.35 | 88.29 | 1,325.38 | 562.33 | 552.96 | 221.41 | 73.18 | 17.36 | 11.05 | 0.54 |
Shareholders Equity per Share |
1.61 | 90.46 | 1,369.51 | 565.22 | 550.49 | 323.08 | 98.77 | 24.16 | 13.76 | 0.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.61 | 90.46 | 1,369.51 | 565.22 | 550.49 | 323.08 | 98.77 | 24.16 | 13.76 | 0.26 |
Free Cash Flow |
(1.78) | (2.79) | (6.65) | (7.42) | (9.79) | (15.62) | (7.44) | (7.00) | (8.10) | (8.64) |
Working Capital |
3.89 | 14.86 | 12.98 | 4.64 | 6.16 | 6.28 | 9.33 | 6.72 | 11.03 | 0.72 |
Capital Expenditures |
(0.01) | (0.03) | (0.03) | (0.04) | 0.00 | (0.04) | (0.16) | (0.01) | — | — |
Net Current Asset Value |
3.89 | 14.86 | 12.98 | 4.39 | 5.97 | 5.89 | 9.32 | 6.07 | 10.72 | 0.72 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.79 | 0.49 | 0.86 | — |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.54 | 2.19 | 2.80 | 0.28 | 0.37 | 0.21 | 0.28 | 0.18 | 0.21 | 0.93 |
Cash ROIC |
(20.52%) | (9.03%) | (23.73%) | (61.94%) | (65.39%) | (99.57%) | (35.34%) | (42.48%) | (33.02%) | (261.20%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.81 | 23.74 | 15.00 | 12.09 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.05 | 0.10 | 0.08 | 0.24 | 1.36 | 2.14 | 2.24 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.33 | 2.44 | 2.93 | — |
Average Days of Payables |
0.00 | 0.00 | 6,081.01 | 4,389.57 | 4,904.85 | 1,614.92 | 214.89 | 172.65 | 138.83 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,665.47 | 215.91 | 129.88 | 108.42 | — |
Average Receivables |
0.04 | 0.03 | 0.05 | 0.06 | 0.03 | 0.05 | 0.17 | 0.31 | 0.41 | — |
Average Payables |
— | — | 1.40 | 1.40 | 1.87 | 2.28 | 2.01 | 1.63 | 1.44 | 1.54 |
Average Inventory |
— | — | — | — | — | — | 2.05 | 1.43 | 1.10 | — |
Average Assets |
0.49 | 8.57 | 15.80 | 11.62 | 8.79 | 11.28 | 13.45 | 12.96 | 13.70 | 9.31 |
Average Common Equity |
2.67 | 10.17 | 14.93 | 10.06 | 6.63 | 8.23 | 10.58 | 10.65 | 11.32 | 7.25 |
Columns are period end dates